Cambridge Healthtech Institute’s 9th Annual

Bispecific Antibody Therapeutics

Combination Therapy & Engineering Multi-Specificity

January 23-24, 2020

Part of the Antibody Therapeutics pipeline

CHI’s Bispecific Antibody Therapeutics conference explores the challenges of engineering multi-specificity to achieve more effective therapies that bind to at least two targets simultaneously. The conference examines how these molecules are used to fight a wide array of diseases, as well as in combination therapy for enhanced effects in the fight against cancer. Along with increased efficacy, Bispecific Antibody Therapeutics can also optimize expenses by reducing the cost of development and clinical trials. Case studies highlight novel engineering approaches and platform constructs that improve safety, stability, enhanced targeting, and manufacturability.

Preliminary Agenda


KEYNOTE PRESENTATION: The Landscape of Multi-Specific Antibodies

Partha S. Chowdhury, PhD, Senior Director and Head, Antibody Discovery, Sanofi Genzyme

Building Blocks for Bispecific and Trispecific Antibodies

Stephen Demarest, PhD, Senior Research Fellow, Protein Biosciences, Eli Lilly & Co.

Maximizing Therapeutic Potential of Bispecific Antibodies and Cytokines by Affinity and Avidity Engineering

David E. Szymkowski, PhD, Vice President, Cell Biology, Xencor, Inc.

Development of NM21-1480, A Trispecific Anti-PD-L1x4-1BBxhSA Antibody Fragment

Sebastian Meyer, PhD, Chief Operating Officer, Numab Therapeutics AG


Advancing a Novel T Cell Engaging Bispecific Antibody that Induces Lysis of Small Cell Lung Cancer Cells In Vitro and Shows Potent T Cell Re-Directed Anti-Tumor Activity In Vivo

Justin Scheer, PhD, Director, Protein and Antibody Engineering, Boehringer Ingelheim

Benchmarking T Cell-Redirecting Therapies for Cancer: Comparing CD3-Bispecifics and CAR T Cells

David J. DiLillo, PhD, Senior Staff Scientist, Immuno-Oncology, Regeneron Pharmaceuticals


Modulating the Immune System with Multi-Specific Antibodies in Cancer

Nathan Trinklein, PhD, Chief Technology Officer, TeneoBio, Inc.

Engineered Multispecific Antibodies for Targeted Inhibition of Cancer Metastasis

Jamie B. Spangler, PhD, Assistant Professor, Biomedical Engineering and Chemical & Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University

ATOR-1015, A Bispecific CTLA-4 x OX40 Antibody, Induces Anti-Tumor Effects Through Tumor-Directed Immune Activation

Christina Furebring, PhD, Senior Vice President, Preclinical Development, Alligator Bioscience

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Traditional Chinese
Simplified Chinese

Update History
Sponsor updated

2020 Conferences & Training Seminars